Is Buprenorphine legal in Trinidad and Tobago?
- Legal status
- Buprenorphine is placed under the Dangerous Drugs Act, Chapter 11:25, on the reading recorded for Trinidad and Tobago, which was taken across the First and Second Schedules together with Legal Notice No. 345 of 2019. The dossier records «buprenorfina» against this row, and that is the term the Act was searched under rather than an entry the Act prints; it is reproduced character for character as the dossier holds it. That string is a Spanish language form, and Chapter 11:25 is an Act enacted in English, so the recorded form is a fact about the dossier's record rather than about the printed schedule; the English schedule word is what governs, and the row turns on chemical identity rather than on spelling. The row reached that placement by the named schedule route, on a reading dated 20 September 2026. The boundary it had to settle before the entry could be assigned is that it checks the semisynthetic opioid entry rather than treating every opioid medicine alike. Placement fixes what the material is for the Act and nothing beyond that: authorisation, purpose, any preparation exception and the conduct actually charged are separate questions, and sections 3 and 5 treat them separately.
- Consequences if caught
- Capital exposure: none. No limb of the Dangerous Drugs Act, Chapter 11:25, carries a capital penalty, so this row's placement does not move that answer in either direction, and the ceiling the Act reaches on a settled entry is life imprisonment rather than death. Trinidad and Tobago does retain capital punishment for murder, which is a different statute and a different offence, so a flat claim that the country has no death penalty would be wrong even where it is right about this Act. No per-substance amount is printed for this row at all. Section 5 of Chapter 11:25, as amended by Act No. 24 of 2019, supplies the trafficking ceiling and section 3 carries the possession offence, so the section charged rather than a printed weight is what sets the exposure. Nothing attaches to a street name. The exposure follows the identification, and what has to be identified here is a partial opioid agonist dispensed as a sublingual tablet, a film or a patch. The conduct charged does the rest of the work. Possession, possession for the purpose of trafficking and trafficking are different sections carrying different ceilings, and the same material will support any of them depending on what else is proved.
- If prescribed or medical
- The dossier records no traveller import scheme, no permit route and no prescription rule for Trinidad and Tobago, so this row defers on that branch rather than inventing one. The country level position that can honestly be stated is the general one: a foreign prescription is evidence about a patient, it is not a Trinidad and Tobago authorisation, and it does not become one at the border. Attached to this row, the placement is settled, which means that any lawful carry would have to rest on an authorisation and never on the amount. It is dispensed both for pain and for opioid dependence, and the dependence indication is the one most likely to be questioned, so the prescriber's letter matters more here than it usually does.
- Documentation
- Carry the dispensing label, the prescriber's letter and the treatment period. A film or a patch is a medicine even when it does not look like one, and a partly used patch pack is still the dispensed product. The entry recorded for this row, «buprenorfina», was read on 20 September 2026 across the First and Second Schedules of Chapter 11:25 and Legal Notice No. 345 of 2019. Whatever is carried, carry it in the container it was issued in, with the paper that names the patient, the substance, the dose and the period. A container separated from its label is the commonest way a lawful supply stops looking like one.
- Trinidad and Tobago, Dangerous Drugs Act, Chapter 11:25, First and Second Schedules, read with Legal Notice No. 345 of 2019 and with sections 3 and 5, section 5 as amended by the Dangerous Drugs (Amendment) Act No. 24 of 2019
- read as at 20 September 2026. The two real hyperlink targets held for the whole document are https://laws.gov.tt/ttdll-web/revision/download/46934?type=act and https://www.ttparliament.org/wp-content/uploads/2022/01/a2019-24g.pdf, and both are document level. This citation is document level and not per substance: the links column for this row holds the constructed text «buprenorphine schedule | buprenorphine penalty», which is a label and not a hyperlink, so no address in this field points at this row's entry rather than at the instrument as a whole. The row's own evidence is the recorded entry «buprenorfina», taken by the named schedule route. One provenance caution belongs on this row. The term the dossier records is a Spanish language form while Chapter 11:25 is enacted in English, so the record's term and the instrument's language do not match, and the citation should be read with that mismatch in view. The line this reading had to hold for this row in particular is that it checks the semisynthetic opioid entry rather than treating every opioid medicine alike.
Court records
We have not yet assessed whether court records are publicly available for this jurisdiction.
Buprenorphine in related jurisdictions
Other substances confirmed in Trinidad and Tobago
Drug laws and enforcement change and vary within a country. This is not legal advice. Always confirm with Trinidad and Tobago’s embassy or official drug authority before traveling; penalties can be severe, including imprisonment.
Before you travel
Verify current rules with the destination country’s official drug authority and your own country’s embassy before traveling. Find the destination’s U.S. embassy & official country guidance →
Non-U.S. travelers: check your own government’s travel advisory and embassy.
If you’re detained or arrested abroad
Contact your own country’s embassy or consulate in the destination immediately, not the destination’s authorities. U.S. citizens: contact the nearest U.S. embassy/consulate and the U.S. State Department at +1-202-501-4444 (from abroad). If a U.S. citizen is arrested or detained abroad →
